SWK Holdings Corp

SWK — Q3 2020 Earnings Presentation

32 slides from SWK's earnings presentation, Nov 17, 2020

  1. Slide 1: Collaborative Approach to Life Science Financing Q3 2020 Shareholder Presentation

    1 Collaborative Approach to Life Science Financing Q3 2020 Shareholder Presentation November 16, 2020

  2. Slide 2: Forward-looking and Cautionary Statements

    2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu

  3. Slide 3: SWK Holdings - Overview

    SWK Holdings - Overview 3 CONFIDENTIAL Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $20mm financings, a market niche that is largel

  4. Slide 4: SWK Holdings - Segments

    4 SWK Holdings - Segments CONFIDENTIAL LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Product acquisitions • Peptelligence ® dosing technology • CDMO services • 505b2 drug development SWK operates through two segments: Life Science Sp

  5. Slide 5: Life Science Finance Opportunity

    5 Life Science Finance Opportunity CONFIDENTIAL Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/midsized life science cos - Few participants exist for sub - $20mm life science financings Life science products are highly portable - Appr

  6. Slide 6: Value Creation Strategy

    6 Value Creation Strategy CONFIDENTIAL Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other equity - like upside features to enhance return p

  7. Slide 7: Book Value Components

    7 Book Value Components CONFIDENTIAL Tangible Finance Book Value / Share = $15.52 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma • In August 2019, SWK paid $21.

  8. Slide 8: Corporate Milestones

    8 Corporate Milestones CONFIDENTIAL 2014 x $113mm raised through private placement and rights offering x Ended year with $93mm yielding assets 2015 x Winston Black named CEO x 1/10 effective reverse stock split x Ended year with $99mm yielding assets 2016 x Team rebuilt and investment process improv

  9. Slide 9: Finance Segment Portfolio Overview: 3Q20

    86% 13% 1% Portfolio Composition First Lien Royalty Warrants 9 Finance Segment Portfolio Overview: 3Q20 CONFIDENTIAL * Finance receivables plus long - term marketable investments; does not include new or repaid finance receivables closed post - quar ter ** Short term marketable investments and warra

  10. Slide 10: Financial Snapshot

    10 Financial Snapshot CONFIDENTIAL * Defined as finance receivables plus long term marketable investments ** Eliminates provision for income taxes, Enteris intangibles amortization, and non - cash mark - to - market changes on warrant asset s and equity securities; see reconciliation on page 28; 201

  11. Slide 11: Financing Strategy

    11 Financing Strategy CONFIDENTIAL SWK Targets Low - to - Mid Teens Effective Yields 3Q20 Finance Segment Effective Yield was 13.4% * Finance receivables plus long - term marketable investment; Includes non - accruals ** Effective yield is the rate at which income is expected to be recognized pursua

  12. Slide 12: Current Structured Credit Portfolio

    12 Current Structured Credit Portfolio CONFIDENTIAL Eton Pharmaceuticals 11.14.19 $15 million – Structured Credit Misonix 9.27.19 $30 million – Structured Credit

  13. Slide 13: Current Royalty Portfolio

    13 Current Royalty Portfolio CONFIDENTIAL

  14. Slide 14: Portfolio Realizations

    14 Portfolio Realizations As of November 13, 2020 SWK has exited 18 financings for a total 1.2x CoC return and 20% weighted average IRR ̶ 15 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 32% IRR ̶ SynCardia position was sold to distressed private equity firm with

  15. Slide 15: Portfolio Realizations to Strategic Buyers

    15 Portfolio Realizations to Strategic Buyers Ten realizations to strategic buyers demonstrated a median 28 % LTV of SWK’s original loan value Seven of the ten businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology CONFIDENTIAL $ in mm Target

  16. Slide 16: Sourcing

    16 Sourcing SWK has a well - developed and diversified sourcing network SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $20mm financings From 2017

  17. Slide 17: Financing Structures

    Financing Structures 17 CONFIDENTIAL Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support p

  18. Slide 18: Value Proposition to Partners

    18 Value Proposition to Partners Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive and diff

  19. Slide 19: Historical Financing: Narcan Royalty

    Historical Financing: Narcan Royalty 19 CONFIDENTIAL OPPORTUNITY SOLUTION • Opiant is a publicly traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration

  20. Slide 20: Historical Financing: Galil Medical

    Historical Financing: Galil Medical 20 CONFIDENTIAL OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sale

  21. Slide 21: Enteris BioPharma Acquisition – A Transformational Opportunity

    Enteris BioPharma Acquisition – A Transformational Opportunity 21 CONFIDENTIAL • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of

  22. Slide 22: Enteris Commercial Platform

    Commercial Platform 22 Enteris Corporate Overview CONFIDENTIAL Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence technology allows for oral delivery of drugs that are typically inject

  23. Slide 23: Enteris: Cara Therapeutics and Oral KORSUVA

    Enteris: Cara Therapeutics and Oral KORSUVA Б 23 CONFIDENTIAL Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris’ Peptelligence technology • Currently the subject of three separate late - stage clinical trials for pruritus; Cara recent announcement to expand investigation i

  24. Slide 24: Leadership Team

    24 Leadership Team CONFIDENTIAL Winston Black Chief Executive Officer • Appointed CEO in 2016 • Co - founded PBS Capital Management • Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer • Appointed CFO

  25. Slide 25: SWK – Rapidly-Growing Life Science Focused Specialty Finance Company

    25 SWK – Rapidly - Growing Life Science Focused Specialty Finance Company CONFIDENTIAL Custom financing solutions for commercial - stage healthcare companies and royalty owners Targeting $5mm to $20mm financings, a niche that is largely ignored by larger market participants Focus is secured financin

  26. Slide 26: Balance Sheet

    $ in 000s Sep-20 Dec-19 Dec-18 Dec-17 Dec-16 ASSETS Cash and cash equivalents 9,314$ 11,158$ 20,227$ 30,557$ 32,182$ Interest and accounts receivable, net 4,608 2,554 2,195 1,637 1,054 Marketable investments 1,136 1,802 - 1,856 2,621 Other current assets 1,911 1,087 138 126 240 Total current assets

  27. Slide 27: Income Statement

    $ in 000s, except per share amounts LTM 3Q20 Dec-19 Dec-18 Dec-17 Dec-16 Revenues Finance receivable interest income, including fees 31,612$ 30,117$ 25,978$ 26,877$ 15,747$ Pharmaceutical development 3,548 621 - - - Marketable investments interest income - - - - 92 Income related to investments in u

  28. Slide 28: Cash Flow Statement

    $ in 000s,* LTM 3Q20 Dec-19 Dec-18 Dec-17 Dec-16 Cash flows from operating activities: Consolidated net income $9,634 $23,828 $6,195 $8,251 $32,041 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entity - - - (10,530) (6,219

  29. Slide 29: Reconciliation of Non-GAAP Adjusted Net Income

    29 Reconciliation of Non - GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas

  30. Slide 30: Reconciliation of Non-GAAP Specialty Finance Net Income

    30 Reconciliation of Non - GAAP Specialty Finance Net Income CONFIDENTIAL The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the

  31. Slide 31: Contact Information

    31 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Winston Black: ̶ Phone: 972.687.7251 ̶ Email: [email protected] • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: ̶ 14755 Preston Road, Ste 105 Dallas

  32. Slide 32: Collaborative Approach to Life Science Financing

    32 Collaborative Approach to Life Science Financing

SWK Holdings — Q3 2020 Earnings Presentation on 6ix